IDEAYA Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4): https://lnkd.in/guGXtnFe
IDEAYA Biosciences
Biotechnology Research
South San Francisco, California 13,381 followers
Synthetic lethality precision medicine oncology company pursuing– an emerging class of precision medicine targets.
Über uns
IDEAYA is an oncology-focused precision medicine company. Our teams are committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. We are advancing therapeutics that have the potential to be first-in-class and/or best-in-class, with a primary focus in synthetic lethality – an emerging class of precision medicine targets. IDEAYA is headquartered in South San Francisco, California.
- Website
-
https://www.ideayabio.com
External link for IDEAYA Biosciences
- Industrie
- Biotechnology Research
- Größe des Unternehmens
- 51-200 Mitarbeiter
- Hauptsitz
- South San Francisco, California
- Typ
- Öffentliches Unternehmen
- Gegründet
- 2015
- Spezialitäten
- Synthetic Lethality and Precision Medicine
Standorte
-
Primäre
Wegbeschreibung erhalten
7000 Shoreline Court
350
South San Francisco, California 94080, US
Employees at IDEAYA Biosciences
Aktualisierungen
-
IDEAYA Reports Second Quarter 2024 Financial Results and Provides Business Update: https://lnkd.in/gTZpXntT
-
IDEAYA Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen: https://lnkd.in/gqeDvTxH
-
-
IDEAYA to Participate in Upcoming August 2024 Investor Relations Event: https://lnkd.in/g8UsAEwF
IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event
media.ideayabio.com
-
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares: https://lnkd.in/gK4NkvCh
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
media.ideayabio.com
-
IDEAYA Announces Pricing of Public Offering: https://lnkd.in/gvHKGftk
IDEAYA Announces Pricing of Public Offering
media.ideayabio.com
-
IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants: https://lnkd.in/g95cKRSf
IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
media.ideayabio.com
-
IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer: https://lnkd.in/gnjZ4A94
-
-
IDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP-Deletion Urothelial and Lung Cancer on Monday, July 8, 2024: https://lnkd.in/gFxJayuU
IDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP-Deletion Urothelial and Lung Cancer on Monday, July 8, 2024
media.ideayabio.com
-
IDEAYA Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4): https://lnkd.in/grQHKRbP
Ähnliche Seiten
Jobs durchsuchen
Finanzierung
IDEAYA Biosciences
7 total rounds
Siehe mehr Informationen auf crunchbase
Letzte Runde
Eigenkapital nach dem IPO
Externer Crunchbase Link für die letzte Finanzierungsrunde
US$ 263.0M